Results from a clinical trial of 66 total knee replacement patients revealed that CyMedica Orthopedics’ e-vive™ app-driven muscle strengthening device yielded statistically significant and positive results in patient rehabilitation.
The randomized, controlled trial measured 66 total knee replacement patients, evaluating the effectiveness of the e-vive neuromuscular electrical stimulation and patient engagement system vs. the standard of care (guided exercize therapy with no device). Patients in the e-vive group demonstrated a 12.9% increase in quadriceps strength at three weeks post-op vs. a 29% loss for the standard of care patients.
Cymedica received FDA 510(k) clearance for e-vive in 2017 as a data-driven muscle activation therapy and patient engagement tool for anterior cruciate ligament and total knee replacement patients. The app works with embedded garment sensor technology to transmit data points (e.g. range of motion, activity levels, pain scores, etc.) directly to a secure cloud-based portal, allowing providers to track patient progress and patient-reported measures.
Results from a clinical trial of 66 total knee replacement patients revealed that CyMedica Orthopedics' e-vive™ app-driven muscle strengthening device yielded statistically significant and positive results in patient rehabilitation.
The randomized, controlled trial measured 66 total knee replacement patients, evaluating the effectiveness of...
Results from a clinical trial of 66 total knee replacement patients revealed that CyMedica Orthopedics’ e-vive™ app-driven muscle strengthening device yielded statistically significant and positive results in patient rehabilitation.
The randomized, controlled trial measured 66 total knee replacement patients, evaluating the effectiveness of the e-vive neuromuscular electrical stimulation and patient engagement system vs. the standard of care (guided exercize therapy with no device). Patients in the e-vive group demonstrated a 12.9% increase in quadriceps strength at three weeks post-op vs. a 29% loss for the standard of care patients.
Cymedica received FDA 510(k) clearance for e-vive in 2017 as a data-driven muscle activation therapy and patient engagement tool for anterior cruciate ligament and total knee replacement patients. The app works with embedded garment sensor technology to transmit data points (e.g. range of motion, activity levels, pain scores, etc.) directly to a secure cloud-based portal, allowing providers to track patient progress and patient-reported measures.
Copy to clipboard 
